D
onor-specific transfusion (DST) has the potential to prolong allograft survival or induce tolerance, particularly when it is used in combination with costimulatory blockade. Multiple mechanisms, including deletion and anergy of donor-reactive T cells (1) (2) (3) (4) and generation of regulatory T cells (Tregs) (5-7), have been suggested to mediate the immunosuppressive effect of DST. It has been reported that tolerogenic dendritic cells (DCs) are responsible for the generation of donor Ag-specific Tregs in mice treated with DST plus anti-CD154 Abs (8) . Furthermore, the failure of DST to suppress alloresponses in recipients that lack APCs demonstrates that the indirect Ag-presentation pathway mediates the effect of DST (9) .
Previous studies using CD47 knockout (KO) mice have demonstrated that CD47, a pentaspan membrane glycoprotein that is expressed ubiquitously in all tissues, serves as a marker of self for macrophages and that its interaction with the inhibitory receptor, signal regulatory protein (SIRP)a (also known as CD172a, SHPS-1), on macrophages prevents the engulfment of autologous hematopoietic cells (10) . CD47-SIRPa signaling also reduces the sensitivity of Ab-and complement-opsonized cells to phagocytosis (11) . In addition, SIRPa is expressed on DCs, and its signaling upon CD47 ligation inhibits DC activation and maturation (12) . By using transgenic mice that express a CD11c promoter-driven simian diphtheria toxin receptor (DTR), we observed that CD47-SIRPa signaling regulates the endocytic activity of CD11c + DCs (13) . In this study, we investigated the role of CD47 in inhibition of alloimmune responses by DST. We show for the first time that CD47 expression on donor cells is required for DST-induced immunosuppression. The loss of prolongation of donor skin graft survival in the recipients of CD47 KO DST was associated with rapid activation of recipient CD11c hi DCs and strong anti-donor T cell responses. ) (10, 14) and wild-type (WT) mice. GFP-transgenic CD47 KO mice and CD47 KO mice on the bm1 background were generated by crossing CD47 KO mice with C57BL/6-transgenic (UBC-GFP) 30Scha/J (The Jackson Laboratory) or bm1 mice, respectively. B10.A (H2 a ) and B6/Ly5.2 congenetic mice were purchased from Frederick Cancer Research Facility (National Institutes of Health, Bethesda, MD). Female mice (6-8 wk old) were used in all experiments. Protocols involving animals were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care. used as DST donors for measuring donor chimerism. Full-thickness tail skins (∼1 3 0.5 cm 2 ) from donor and third-party mice were grafted on the dorsum of recipient bm1 mice, sutured with 5-0 silk, and secured with Vaseline gauze and bandage for 7 d. Skin graft survival was followed by daily visual inspection for the first 3 wk and once every 2 d thereafter. Grafts were defined as rejected when ,10% of the graft remained viable.
Materials and Methods
Preparation of CD11c-DTR bone marrow chimeras and CD11c hi cell depletion
Eight-week-old B6 mice received 10.25 Gy total body irradiation from a
137
Cs irradiator followed by reconstitution 6-8 h later with 10 3 10 6 syngeneic bone marrow (BM) cells from WT or CD11c-DTR B6 mice. These BM chimeras were used as DST recipients 8 wk later. CD11c hi cell depletion was performed by i.p. injection of DT (4 ng/gram body weight; Sigma-Aldrich) 12 h before and 24 h after DST.
Preparation of B6 WT-to-CD47 KO BM chimeras CD47 KO B6 mice (8 wk old) received 10.25 Gy total body irradiation from a 137 Cs irradiator followed by reconstitution 6-8 h later with 10 3 10 6 syngeneic lineage-negative BM cells from WT B6 mice (13) . These chimeras were used as DST recipients 9 wk after BM transplantation. We have confirmed macrophage tolerance to CD47 KO cells in these chimeras by measuring the survival of WT versus CD47 KO B6 splenocytes as previously described (13) .
Flow cytometric analysis of CD86 and MHC class II expression on recipient CD11c + DCs
Spleen cells were prepared from bm1 recipients at the indicated time points after DST and stained with fluorescence-labeled anti-mouse CD4, CD8a, CD11c, CD86, and I-A b (BD Biosciences, San Diego, CA). A rat antimouse FcgR mAb (2.4G2) was used to block the nonspecific binding of labeled mAbs, and HOPC1 (murine IGg2a) and rat IgG (BD Biosciences) were used as isotype controls. Data were collected using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA).
Mixed leukocyte (lymphocyte) reaction
Spleen cells were prepared from B6 mice 7 d after injection of 1 3 10 7 splenocytes from CD47 +/+ (WT), CD47 +/2 or CD47 2/2 (KO) bm1 donors; total CD4 + and CD8 + T cells were purified and used as the responders. Total T cells were purified via negative selection by MACS using pan-T microbeads (Miltenyi Biotec, Auburn, CA). CD4 + and CD8 + T cells were purified via negative selection by MACS using pan-T plus anti-CD8 microbeads and pan-T plus anti-CD4 microbeads, respectively. The responder cells were cultured in a 96-well plate (2 3 10 5 cell per well) alone (unstimulated control), or stimulated with an equal number of irradiated (30 Gy) In vivo assay for CD8 T cell proliferation rBm1 mice (CD45.2 + ) were injected with 1 3 10 7 CD45.1 + B6 donor splenocytes. Seven days later, splenocytes were prepared from bm1 recipients, and labeled with CFSE (Molecular Probes, Eugene, OR) as described (15) . CFSE-labeled cells (2 3 10 7 ) were injected through the tail vein into lethally (9.5Gy) irradiated CD45.1 + B6 mice. Splenocytes were prepared from the B6 recipients 3 d after adoptive transfer of CFSE-labeled cells and stained with PE-conjugated anti-mouse CD45.1 (A20) plus allophycocyanin-conjugated anti-mouse CD4 or CD8 mAbs. A rat anti-mouse FcgR mAb (2.4G2) was used to block the nonspecific binding of labeled mAbs, and HOPC1 (murine IGg2a) and rat IgG (BD Biosciences) were used as isotype controls. Proliferation of adoptively-transferred bm1 CD4 (i.e., CD45.1 
Statistical analysis
Graft survival data are presented as Kaplan-Meier survival curves and differences between groups were analyzed by the log-rank test using GraphPad Prism (version 4; San Diego, CA). Differences between group means were tested using Student t test by Microsoft Excel (Redmond, WA) software; p , 0.05 was considered significant.
Results

DST using CD47 KO donor cells fails to prolong donor skin graft survival or inhibit anti-donor T cell alloresponses
Bm1 mice were injected i.v. with 1 3 10 7 splenocytes from MHC class I disparate CD47 KO or WT B6 donor mice and grafted with skin from WT B6 donors 7 d later. All control bm1 mice that did not receive DST rejected the B6 skin grafts, with a median survival time (MST) of 20 d (Fig. 1A) . Compared with non-DST controls, DST using WT donor splenocytes significantly extended the survival of B6 donor skin in bm1 mice (MST = 42.5 d; p , 0.001 compared with non-DST controls). In contrast, DST with CD47 KO B6 splenocytes accelerated B6 skin graft rejection in bm1 mice (MST = 16 d; p , 0.001 and p , 0.01 compared with WT DST and non-DST groups, FIGURE 1. CD47 expression on donor cells is required for prolongation of donor skin grafts by DST. A and B, Donor (B6, A) and third-party (B10.A, B) skin allograft survival in naive bm1 mice (non-DST) and bm1 mice that received DST (i.e., 1 3 10 7 splenocytes) from WT (WT-DST) or CD47 KO (KO-DST) B6 donors 7 d before skin grafting. Results in A and B are the combined data of seven and two independent experiments, respectively. C and D, In vitro MLR. Total and purified CD4 + or CD8 + T cells were prepared from recipient splenocytes at day 7 after DST and cocultured with an equal number of irradiated (30 Gy) splenocytes (stimulators) from B6 (donor) or B10A (third-party) mice. Results (mean 6 SD) are presented as a stimulation index, and the data of two independent experiments are combined (n = 5 per group). Shown are anti-donor and anti-third-party MLR of total T cells (C) and anti-donor MLR of purified CD4 + and CD8 + T cells (D). E, In vivo MLR. Splenocytes were harvested from non-DST controls (n = 5) and the recipients of WT (n = 9) or CD47 KO (n = 5) DST 7 d after DST, labeled with CFSE, and adoptively transferred into lethally irradiated (9. respectively). The DST effect was donor specific, as the third-party skin allografts were rejected similarly by all groups (Fig. 1B ). These data demonstrate that CD47 expression on donor cells is required for suppression of alloresponses by DST, and they suggest that DST may sensitize the recipient mice to donor alloantigens if the donor cells do not express CD47.
We also measured anti-donor T cell responses by in vitro MLR assay, in which T cells prepared from non-DST controls and DST recipients 7 d after DST were used as the responders. Consistent with donor skin graft survival, T cells from WT DST recipients showed no proliferative response to the DST donor stimulators (p , 0.01 compared with non-DST controls), but proliferated normally to the third-party stimulators (Fig. 1C) . CD47 expression on DST donor cells was required for DST-induced donor-specific unresponsiveness. Compared with WT DST recipient T cells, T cells from CD47 KO DST recipients showed significantly increased anti-donor (p , 0.01), but comparable anti-third-party MLR. Furthermore, MLR assay using purified CD4 + or CD8 + T cell responders revealed that the anti-donor MLR in this MHC class I (H-2k)-mismatched combination was predominantly mediated by CD8 + T cells, and that WT, but not CD47 KO, DST was able to suppress the anti-donor MLR of CD8 + T cells (Fig. 1D ). We next measured the anti-donor T cell responses using an in vivo proliferation assay (15) . Splenocytes harvested from bm1 recipients (CD45.2 + ) of CD47 KO or WT B6 DST 7 d after DST and from non-DST controls (i.e., naive bm1 mice) were labeled with CFSE and injected into lethally-irradiated CD45.1 + B6 mice. The in vivo proliferation of injected bm1 CD4 (i.e., CD45.1 2 CD4 + ) and CD8 (i.e., CD45.1 2 CD8 + ) T cells was analyzed by flow cytometry 3 d after adoptive cell transfer. As shown in Fig. 1E , CD8 T cells from bm1 mice receiving CD47 KO DST demonstrated markedly increased proliferation in lethally irradiated B6 mice compared with those from the WT DST group (p , 0.01). However, no significant difference was detected between CD8 T cells from naive bm1 mice (non-DST controls) and bm1 mice receiving WT DST. The data suggest that T cells from the CD47 KO DST recipients may mediate even stronger anti-donor responses than those from non-DST controls, which is consistent with the results of donor skin graft survival for these groups (Fig. 1A) . Similar to the in vitro MLR (Fig. 1D) , CD4 T cells from neither group exhibited significant proliferation in B6 mice (Fig. 1E) .
Mice receiving repeated administration of CD47 KO DST show no improvement in donor skin graft survival Because CD47 KO hematopoietic cells are rejected rapidly by macrophages and DCs after injection into WT mice (10, 13, 17), we investigated whether the early loss of donor chimerism is responsible for the failure of CD47 KO DST to suppress anti-donor alloresponses. We first assessed the effect of multiple injections of CD47 KO splenocytes on donor skin graft survival. We injected 7 WT (sWT-DST) or CD47 KO (sKO-DST) B6 splenocytes at day 27, or four daily injections of CD47 KO B6 splenocytes (1 3 10 7 per injection) from day 27 to day 24 (mKO-DST), followed by skin grafting from B6 donors at day 0. Untreated bm1 mice were used as non-DST controls. B, Bm1 mice received 1 3 10 7 WT or CD47 KO B6 splenocytes, or a mixture (1 3 10 7 each) of WT and CD47 KO B6 splenocytes 7 d before donor skin grafting (n = 6 per group). Data shown are donor skin graft survivals in the indicated groups. Fig. 2A ; p , 0.05 compared with non-DST controls). However, acceleration of donor skin rejection was seen in both single and multiple CD47 KO DST groups. The survival of donor skin grafts was similar between bm1 mice that received single versus multiple CD47 KO DST (MSTs for single and multiple DST groups were 11.5 and 10.5 d, respectively), and significantly shorter than that in non-DST controls (MST, 20.5 d; p , 0.05). These data suggest that the rapid loss of donor chimerism seems unlikely to be the major mechanism for the failure to inhibit donor graft rejection in CD47 KO DST recipients.
Reduced donor skin graft survival in recipients of mixed WT and CD47 KO DST compared with those receiving only WT DST
We also compared donor skin rejection in bm1 mice receiving WT, CD47 KO, or a mixture of WT plus CD47 KO splenocytes. Although bm1 mice receiving mixed WT and CD47 KO DST displayed delayed rejection of donor skin grafts compared with those receiving CD47 KO DST (p , 0.05), donor skin survival in these mice was significantly decreased versus survival in bm1 mice that received WT DST (p , 0.05; Fig. 2B ). Because WT donor cells are not susceptible to phagocytosis, even when injected together with CD47 KO cells in WT mice (13), these results further suggest that the loss of donor chimerism is unlikely to be responsible for the inability of CD47 KO DST to suppress anti-donor alloresponses. Furthermore, the reduced ability of WT DST to prolong donor skin survival in bm1 mice receiving simultaneous CD47 KO DST indicates that CD47 KO DST made the recipients less responsive to WT DST.
CD47 KO DST from bm1 donors fails to suppress alloresponses in WT→CD47 B6 full hematopoietic chimeras
We have previous shown that the lack of CD47 expression on nonhematopoietic cells can induce macrophage tolerance to CD47 KO cells, and that WT macrophages developing WT→CD47 KO BM chimeras do not phagocytose CD47 KO splenocytes (13) . To firmly determine whether the rapid clearance of donor cells is responsible for the inability of CD47 KO DST to prolong allograft survival, we compared the immunosuppressive effects of WT versus CD47 KO DST in preestablished WT→CD47 KO full BM chimeras. Full WT hematopoietic chimeras were established by injection of WT B6 lineage-negative BM cells into lethally irradiated CD47 KO B6 mice, and used as DST recipients 9 wk later. The chimeras that received no treatment (non-DST controls) or DST from WT or CD47 KO bm1 donors were grafted with WT bm1 skin 1 wk after DST. Compared with non-DST control chimeras, WT, but not CD47 KO, DST was able to significantly prolong the survival of donor skin allografts in the preestablished BM chimeras (Fig. 3). These results indicate that the rapid loss of donor chimerism is not the major mechanism for the inability of CD47 KO DST to suppress alloresponses.
DST using CD47 heterozygote cells induces better donor graft survival, but still worse than WT DST Although CD47 heterozygote (CD47 +/2 ) cells exhibit decreased CD47 expression and mediate reduced CD47-SIRPa signaling relative to WT cells, the level of CD47 expression on CD47 +/2 cells is sufficient to inhibit phagocytosis upon transplantation into normal syngeneic WT mice (Fig. 4A, 4B) (11) . To determine whether the density of CD47 expression on donor cells correlates with DSTinduced immunosuppression, we compared the survival of donor skin grafts in bm1 mice receiving DST from WT, CD47 +/2 , or CD47 2/2 B6 donors. Again, CD47 2/2 DST accelerated donor skin rejection (MST, 11 d) compared with non-DST controls (MST, 13 d; Fig. 4C ; p , 0.05). Although prolongation of donor skin grafts was seen in bm1 mice receiving CD47 +/2 DST (p , 0.01 compared with non-DST and CD47 KO DST groups), graft survival in these mice was significantly shorter than that in the recipients of WT DST (p , 0.05; MST of donor skin grafts were 36 d and 47 d for CD47
+/2 DST and WT DST groups, respectively). We also compared the anti-donor MLR responses of T cells prepared from these mice at day 7 post-DST. Unlike CD47 KO DST, CD47 +/2 DST was able to suppress anti-donor responses of the recipient T cells at the early time (Fig. 4D) . The levels of T cell proliferation in response to donor stimulators at day 7 post-DST were comparable between CD47 +/2 DST and WT DST recipients. These results suggest that the immunosuppressive strength of DST is positively correlated with the density of CD47 expression on donor cells.
Recipient CD11c
hi DCs in CD47 KO, but not WT or CD47 +/2 , DST recipients show rapid activation and contribute to donor skin graft rejection Splenocytes were collected shortly after DST (5 and 24 h), and the expression of CD86 and MHC class II on CD11c hi cells was determined by flow cytometry. The levels of CD86 and MHC class II (I-A b ) expression on splenic CD11c hi DCs from bm1 mice receiving WT or CD47 +/2 DST remained similar to those from non-DST control (i.e., naive) bm1 mice (Fig. 5A , 5B). In contrast, CD47 KO DST resulted in rapid upregulation of CD86 and MHC class II expression on recipient CD11c hi DCs. A significant increase in the percentages of CD86 + and I-Ab hi splenic CD11c hi DCs was detected in CD47 KO DST-treated bm1 mice 5 and 24 h after DST compared with non-DST controls, as well as WT and CD47 +/2 DST-treated bm1 mice (Fig. 5A , 5B). Interestingly, CD47 KO DST-induced upregulation of CD86 and MHC class II was detected only in CD8a 2 (mainly CD4 + ), but not in CD8a + , CD11c
hi DCs (Fig. 5C, 5D ). To understand whether the early CD11c hi DC activation contributes to graft rejection in the recipients of CD47 KO DST, we compared donor skin graft survival in recipient mice with or without transient depletion of host CD11c hi DCs at the time of DST. To prevent DT-induced morbidity and mortality, we used CD11c-DTR BM (CD11c-DTR→B6) chimeras, in which DTR is expressed only on CD11c + hematopoietic cells, as the recipients of DST. DC depletion in CD11c-DTR BM chimeras was achieved by injection of DT at days 21 and 1 with respect to DST. CD11c + DC depletion in DT-treated CD11c-DTR B6 mice and CD11c-DTR BM chimeras lasts for 2 d (18, 19) . WT B6 BM (B6→B6) chimeras that were similarly treated with DT were used as controls. Transient deletion of CD11c hi cells by DT (Fig. 6A ) did not significantly affect donor skin survival in non-DST controls (Fig. 6B) and WT DST recipients (Fig. 6C) . However, transient deletion of CD11c hi cells significantly delayed donor skin rejection in the recipients of CD47 KO DST (Fig.  6D) , indicating that CD11c hi DCs might contribute to graft rejection in CD47 KO DST recipients.
Discussion
Our data demonstrate that CD47 expression on donor cells is required for suppression of alloresponses by DST. We show that DST using CD47 KO donor cells does not prolong donor skin graft survival and may even accelerate rejection in an MHC class I (H2k)-mismatched mouse model, in which WT DST can significantly prolong donor skin graft survival. Consistent with the survival time of donor skin grafts, T cells from recipients of CD47 KO, but not WT, DST mediated strong anti-donor responses. Furthermore, unlike recipient DCs in WT DST recipients, recipient DCs in mice receiving CD47 KO DST exhibited rapid activation and contributed to donor allograft rejection.
The role for donor chimerism in DST-induced immunosuppression remains incompletely understood. It has been shown that transfusion of donor BM cells neither extends allograft survival nor mediates alloreactive T cell deletion in a model, in which both can be achieved via the transfusion of donor splenocytes (20) . However, peripheral deletion of donor-reactive T cells was found to contribute to tolerance induction by DST (2-4). Because CD47 KO hematopoietic cells are rapidly phagocytosed by macrophages and DCs after injection into WT mice (10, 13, 17) , it is possible that the failure of CD47 KO DST to suppress alloresponses is due to the early loss of donor chimerism. However, our data indicate that the failure of CD47 KO DST to suppress alloresponses cannot be explained by the rapid loss of donor chimerism. First, neither repeated administration of CD47 KO DST nor mixed WT and CD47 KO DST improved donor skin graft survival to the extent mediated by WT DST. In addition, despite that WT and CD47 +/2 DST recipients exhibited comparable levels of donor chimerism, FIGURE 6 . Transient depletion of recipient CD11c hi DCs delays donor skin graft rejection in recipients of CD47 KO DST. Established CD11c-DTR BM chimeras and WT B6 BM chimeras received two injections of DT at days 28 and 26, DST from WT, or CD47 KO bm1 donors at day 27, and skin grafting from bm1 donors at day 0. A, Flow cytometric analysis of GFP CD47 +/2 DST mediated significantly reduced prolongation of donor skin grafts relative to WT DST. Finally, CD47 KO DST failed to prolong allograft survival in WT→CD47 KO BM chimeras in which macrophages do not phagocytose CD47 KO splenocytes (13) .
SIRPa serves as an inhibitory receptor in DCs, and its signaling upon ligation of CD47 suppresses DC endocytosis (13) and activation (12) . Because host DCs play a critical role in tolerance induction by DST (8, 9) , it is possible that the encounter of recipient DCs with donor cells in the absence of CD47-SIRPa signaling may result in DC activation, leading to stimulation of alloreactive T cells in DST recipients. In this study, we found that significant upregulation of CD86 and class II expression was detected in splenic CD11c
hi DCs from the recipients of CD47 KO, but not WT, DST compared with non-DST (i.e., naive) bm1 controls. hi cells at the time of DST significantly prolonged donor skin survival in mice that received CD47 KO DST. These results suggest that the rapid activation of recipient DCs is likely to be at least one of the mechanisms for the failure of CD47 KO DST to suppress alloresponses. In this study, we could not detect significant anti-donor MLR in the purified splenic CD4 + T cell population. However, by using bm1-specific CD4 T cell lines (derived from immunized B6 mice), Ossevoort et al. (25) reported that CD4 T cells can recognize and respond to synthetic bm1 peptides presented by MHC class II molecules on B6 cells, and the naturally processed bm1 peptide presented by I-A b molecule on bm1 cells. Although the anti-bm1 responses of B6 CD4 T cells is considerably weak (the proliferation of stimulated bm1-specific CD4 T cell lines was only 2-3-fold greater than the nonstimulated controls) (25) , these data indicate that CD4 T cells may provide help to CD8 T cell responses to bm1 Ags. Thus, it is possible that rapid DC activation may stimulate anti-donor responses via activating CD4 T cells in the recipients of CD47 KO DST. Our results also suggest that CD47 expression on donor cells plays an important role in maintaining the immature state of recipient DCs after DST, which was found to be important in the induction of Tregs (26) and T cell tolerance (27) in mice after allogeneic DST. Further study will be required to confirm whether the role for CD47 expression on donor cells in preventing DC activation is mediated by its interaction with SIRPa on recipient DCs.
Although apparently less effective than WT DST, CD47 +/2 DST significantly prolonged donor skin graft survival compared with non-DST controls. Unlike CD47 KO DST, injection of CD47 +/2 splenocytes did not induce early DC activation. The lack of proliferation of T cells from CD47 +/2 DST recipients (as measured at day 7 after DST) indicates that CD47 +/2 DST efficiently suppressed the anti-donor T cell responses at the early time. However, T cells in CD47 +/2 DST recipients may exhibit greater anti-donor responses than those in WT DST recipients at the later times, which were not examined in this study. Nonetheless, the data indicate that the density of CD47 molecules on donor cells is positively correlated with the ability of DST to suppress alloresponses.
We have demonstrated that CD47 expression on donor cells is required for DST-induced suppression of alloimmune responses and prolongation of skin allograft survival. Because CD47-SIRPa interaction is species-specific (28-30), this study also suggests an explanation for the poor effect of DST in the induction of immunosuppression or tolerance in discordant xenogeneic transplantation settings (31) . Although the mechanisms by which CD47 expression regulates alloimmune responses remain largely unknown, this report suggests that CD47 may provide a target for new therapeutic approaches to preventing transplant rejection.
